Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct

American Heart Journal

Volumn 166, Issue 2, 2013, Pages

  Lopes, Renato D ^a   Dickerson, Sheila ^a   Hafley, Gail ^a   Burns, Shana ^a   Tourt Uhlig, Sandra ^a   White, Jennifer ^a   Newby, L Kristin ^a   Komajda, Michel ^b   McMurray, John ^c   Bigelow, Robert ^a   Home, Philip D ^d   Mahaffey, Kenneth W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE DATABASE; STUDY DESIGN;

EID: 84880917306     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.05.005     Document Type: Article

References (24)

1. K.W. Mahaffey, M.T. Roe, and C.K. Dyke Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial Am Heart J 143 2002 242 248
2. P.D. Home, S.J. Pocock, and H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
3. K.W. Mahaffey, G. Hafley, and S. Dickerson Results of a reevaluation of cardiovascular outcomes in the RECORD trial Am Heart J 166 2 2013 240 249
4. K.A. Hicks, H.M.J. Hung, and K.W. Mahaffey Standardized definitions for end point events in cardiovascular trials http://www.clinpage.com/images/ uploads/endpoint-defs-11-16-2010.pdf
5. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction Eur Heart J 21 2000 1502 1513
6. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res Clin Pract 87 2010 4 14
7. S. Wild, G. Roglic, and A. Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
8. S.J. Olshansky, D.J. Passaro, and R.C. Hershow A potential decline in life expectancy in the United States in the 21st century N Engl J Med 352 2005 1138 1145 (Pubitemid 40365358)
9. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
10. Action to Control Cardiovascular Risk in Diabetes Study Group H.C. Gerstein, and M.E. Miller Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2549
11. K.K. Ray, S.R. Seshasai, and S. Wijesuriya Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
12. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
13. S.E. Kahn, S.M. Haffner, and M.A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443 (Pubitemid 44903747)
14. H.C. Gerstein, S. Yusuf, and J. Bosch Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
15. J.R. Wright, Y.C. Ung, and J.A. Julian Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J Clin Oncol 25 2007 1027 1032 (Pubitemid 46596751)
16. M. Henke, R. Laszig, and C. Rübe Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260 (Pubitemid 37324251)
17. B. Leyland-Jones BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 2003 459 460 (Pubitemid 37009952)
18. T.B. Drüeke, F. Locatelli, and N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
19. A.K. Singh, L. Szczech, and K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
20. S.E. Kahn, B. Zinman, J.M. Lachin for the A Diabetes Outcome Progression Trial (ADOPT) study group Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT) Diabetes Care 31 2008 845 851
21. US Food and Drug Administration FDA Briefing Document: Advisory Committee Meeting for NDA 21071 Avandia (rosiglitazone maleate) tablet: July 13 and 14, 2010 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf
22. Woodcock, J. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91.
23. P.D. Home, S.J. Pocock, and H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 2007 28 38 (Pubitemid 47026732)
24. J. Lindsey, and L. Ryan Tutorial in biostatistics methods for interval-censored data Stat Med 17 1998 219 238 (Pubitemid 28043593)